6MW3211 was designed with high binding affinity to hPD-L1 and low affinity to hCD47, which allows 6MW3211 to preferentially bind to hPD-L1 expressing tumor cells followed by CD47/SIRPα signaling disrupting. Here, SIRPA is linked to neoplasm.